IOL Chemicals & Pharmaceuticals Ltd

AI
IOL Chemicals Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents
AI

IOL Chemicals & Pharmaceuticals Ltd

₹ 162 3.41%
20 Aug 11:23 a.m.
iolcp.com BSE: 524164 NSE: IOLCP
About

IOL Chemicals & Pharmaceuticals Ltd is a leading pharmaceutical (APIs) company and is a significant player in the specialty chemicals space. It serves the domestic and export market.[1]

It is the largest player of Ibuprofen (pain killer) globally with a world market share of 35%.[2]

Key Points

Business Segment
a) Pharmaceuticals Segment [1]
Product Portfolio: Ibuprofen, Ibuprofen Lysinate, Ibuprofen Sodium, Dex-Ibuprofen, Metformin HCL, Paracetamol, Clopidogrel, Pantoprazole Sodium, Fenofibrate, Levetiracetam, Lamotrigine, Losartan Potassium

Website BSE NSE
  • Market Cap ₹ 4,765 Cr.
  • Current Price ₹ 162
  • High / Low ₹ 180 / 67.1
  • Stock P/E 27.0
  • Book Value ₹ 61.3
  • Dividend Yield 0.62 %
  • ROCE 11.3 %
  • ROE 8.42 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 22.1%
  • Promoter holding has increased by 4.80% over last quarter.

Cons

  • Stock is trading at 2.64 times its book value
  • The company has delivered a poor sales growth of 3.35% over past five years.
  • Company has a low return on equity of 7.74% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare BSE 1000

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
563 545 520 504 502 526 523 528 552 568 580 619 756
490 481 476 454 452 484 476 465 490 510 523 527 653
Operating Profit 73 64 44 50 51 42 47 63 62 57 57 93 104
OPM % 13% 12% 9% 10% 10% 8% 9% 12% 11% 10% 10% 15% 14%
7 7 8 8 7 6 4 5 7 7 -6 2 8
Interest 4 4 4 3 2 4 4 4 4 3 4 3 4
Depreciation 14 16 16 16 17 18 19 19 20 20 20 20 21
Profit before tax 62 51 32 38 39 26 28 45 46 41 28 71 87
Tax % 25% 26% 28% 25% 24% 26% 26% 30% 25% 26% 25% 25% 26%
46 38 23 28 30 19 21 32 34 30 21 53 64
EPS in Rs 1.57 1.29 0.79 0.96 1.01 0.65 0.70 1.08 1.16 1.02 0.70 1.81 2.20
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
385 580 711 983 1,685 1,894 1,967 2,184 2,217 2,133 2,079 2,319 2,524
373 529 608 863 1,276 1,321 1,375 1,927 1,990 1,901 1,877 2,049 2,213
Operating Profit 11 51 102 120 410 574 592 257 227 232 202 270 310
OPM % 2.9% 9% 14% 12% 24% 30% 30% 12% 10% 11% 10% 12% 12%
1 1 1 6 10 16 24 17 25 30 22 9 11
Interest 59 61 68 64 51 21 6 8 16 16 15 15 14
Depreciation 29 30 30 30 32 36 39 43 46 63 72 80 82
Profit before tax -75 -39 6 31 336 533 571 223 189 183 138 184 226
Tax % -12% 4% 21% 12% 30% 32% 22% 26% 26% 26% 27% 25%
-67 -40 5 28 237 361 445 166 140 135 101 138 168
EPS in Rs -2.80 -1.42 0.17 0.99 8.32 12.70 15.15 5.64 4.77 4.61 3.44 4.69 5.73
Dividend Payout % 0% 0% 0% 0% 0% 5% 8% 14% 17% 22% 23% 21%
Compounded Sales Growth
10 Years: 15%
5 Years: 3%
3 Years: 2%
TTM: 19%
Compounded Profit Growth
10 Years: 19%
5 Years: -20%
3 Years: 2%
TTM: 68%
Stock Price CAGR
10 Years: 19%
5 Years: 6%
3 Years: 29%
1 Year: 60%
Return on Equity
10 Years: 18%
5 Years: 9%
3 Years: 8%
Last Year: 8%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 48 56 56 56 57 57 59 59 59 59 59 59
Reserves 160 129 132 160 417 757 1,202 1,332 1,448 1,553 1,629 1,740
400 453 447 422 284 59 3 44 80 33 117 135
94 135 182 214 184 297 347 526 434 600 577 653
Total Liabilities 702 772 817 852 942 1,170 1,610 1,960 2,021 2,244 2,382 2,587
403 400 374 406 412 469 512 561 751 933 1,170 1,181
CWIP 4 4 21 7 27 19 48 105 90 101 22 96
Investments 0 0 0 0 0 0 1 2 20 21 21 21
295 369 422 439 503 682 1,048 1,292 1,159 1,190 1,168 1,289
Total Assets 702 772 817 852 942 1,170 1,610 1,960 2,021 2,244 2,382 2,587

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
-47 18 83 120 273 471 380 91 123 290 179 214
-5 -27 -23 -50 -63 -184 -317 -121 -119 -191 -154 -198
50 9 -60 -70 -197 -272 -58 -2 -4 -92 46 -29
Net Cash Flow -2 -0 1 -1 13 15 4 -31 -0 7 70 -13
Free Cash Flow -53 -9 61 71 213 391 272 -60 -86 18 -34 44
CFO/OP -413% 34% 82% 105% 83% 102% 88% 60% 75% 144% 97% 93%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 31 55 58 54 43 52 56 79 83 81 90 95
Inventory Days 279 201 201 109 66 64 98 95 77 111 95 91
Days Payable 92 102 115 83 42 62 79 95 74 123 112 118
Cash Conversion Cycle 218 154 144 80 67 55 74 79 86 69 73 68
Working Capital Days 59 39 36 23 43 46 66 71 72 71 58 53
ROCE % -3% 4% 12% 15% 56% 68% 54% 18% 14% 12% 9% 11%

Insights

In beta
Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Export Revenue Share
% of total sales

Log in to view insights

Please log in to see hidden values.

Login
Permanent Employees
count
Pharma Segment Revenue Share
% of total revenue (net of intersegment)
Installed Capacity - Ibuprofen
MTPA
Installed Capacity - Ethyl Acetate
MTPA
Installed Capacity - Paracetamol
MTPA
Non-Ibuprofen Share in Pharma Revenue
% of pharma segment revenue
Regulatory Approvals (CEPs and DMFs)
count
R&D Expenditure (Percentage of Turnover)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

8 Recently
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
48.19% 48.19% 48.19% 48.19% 48.19% 52.62% 52.62% 52.62% 52.62% 52.62% 57.48% 62.28%
2.33% 2.18% 1.40% 1.39% 1.63% 1.49% 1.47% 2.59% 2.25% 2.08% 1.72% 4.87%
0.35% 0.36% 0.29% 0.09% 0.07% 0.08% 0.07% 0.02% 0.05% 0.03% 0.02% 0.43%
49.12% 49.27% 50.11% 50.34% 50.11% 45.81% 45.84% 44.76% 45.10% 45.26% 40.78% 32.41%
No. of Shareholders 1,35,3971,34,2351,30,0031,28,6891,25,9791,26,7011,30,0021,25,0401,36,1291,33,5311,31,5501,19,311

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls